Urmimala Biswas

Kolkata

Senior Equity Research Analyst at Zacks Investment Research

Featured in: Favicon

zacks.com

yahoo.com (+4) Favicon

entrepreneur.com Favicon

nasdaq.com Favicon

247wallst.com Favicon

globes.co.il Favicon

barchart.com Favicon

flipboard.com Favicon

en.globes.co.il

Articles

Will Trump Tariffs Make or Break the Healthcare Space? 3 Stocks to Rely On

2 weeks ago | dailytradealert.com | Urmimala Biswas

The American trade structure is witnessing a transformative shift, thanks to the Trump administration’s sweeping new tariff policy. Within the healthcare industry, the impact seems to be complex and widespread. Apparently, pharmaceuticals are exempt from the steep reciprocal tariffs.
D-Wave Quantum Surges 38% in March: Is QBTS a Smart Buy Now?

3 weeks ago | yahoo.com | Urmimala Biswas

Quantum computing is rapidly emerging as the next great revolution in technology, a field that could one day outpace artificial intelligence (AI) in terms of disruptive potential. This year is proving to be a pivotal period for the industry and especially for D-Wave Quantum Inc. QBTS. In March, the company made headlines with a few groundbreaking achievements. It demonstrated quantum supremacy using its Advantage2 prototype.
3 Medical Services Industry Stocks to Buy as AI Fuels Growth

4 weeks ago | sg.finance.yahoo.com | Urmimala Biswas

Urmimala Biswas Thu, 27 March 2025 at 12:15 pm GMT-5 7 min read In this article: The Medical Services sector is experiencing significant transformation fueled by advancements in technology, increased adoption of value-based care and focus on patient-centric solutions and precision medicine. The rising demand for remote treatment has driven rapid growth in digital healthcare, particularly telemedicine and AI-powered services, utilizing data and analytics.
Fed's Stagflation Fears Weigh, Yet Growth Factors Make BSX Stock a Buy

1 month ago | zacks.com | Urmimala Biswas

Boston Scientific ( - Free Report) is experiencing a temporary cooling-off period after its strong run in 2024, where the stock climbed 54.5%, banking on robust financial performance and product advancements throughout the year. The stock's 3% decline so far in March can be attributed to broader market concerns, especially with the Fed's cautious stance on interest rates and economic conditions.
Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?

1 month ago | zacks.com | Urmimala Biswas

Stereotaxis ( - Free Report) reached a significant milestone last Wednesday when NVIDIA ( - Free Report) took its name for the NVIDIA Connect program. Following the news, Stereotaxis' stock jumped more than 15%, reflecting strong investor confidence in the company’s AI-driven growth trajectory. At a time when the market is hypervigilant about anything linking AI giant NVIDIA, this news came as a breakthrough for STXS.
4 Top PEG Stocks Based on GARP Approach to Smart Investing

1 month ago | zacks.com | Urmimala Biswas

In the equity market, investments always need to be prudently hedged in order to overcome uncertainties and limit losses related to external shocks. A question that often arises is whether one should resort to a value strategy that seeks discounted stocks or opt for growth investing in times of extreme market instability.
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

1 month ago | zacks.com | Urmimala Biswas

Artificial Intelligence (AI) and Machine Learning (ML) play a pivotal role in precision oncology, analyzing vast datasets, identifying patterns and aiding in informed decision-making. Within this domain, digital pathology plays a crucial role, leveraging AI algorithms to detect cancerous cells, classify tumor subtypes and enhance patient outcomes. Among its key focus areas, AI-powered automated image analysis and biomarker identification stand out as major advancements.
Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?

1 month ago | zacks.com | Urmimala Biswas

The global medical cannabis market is experiencing significant growth, driven by increasing legalization, expanding research and rising demand for alternative pain management solutions. Projected to witness a CAGR of 22.5% from 2025 to 2035, the industry presents a highly favorable landscape for companies like Aurora Cannabis ( - Free Report) .
Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?

1 month ago | zacks.com | Urmimala Biswas

Artificial Intelligence (AI)-based healthcare solutions company Tempus AI ( - Free Report) has continued to capture investors’ attention despite reporting weaker-than-expected fourth-quarter 2024 results on Feb. 24, 2025. The earnings miss led to an immediate decline in the company’s share price, raising short-term concerns among investors.
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus

1 month ago | zacks.com | Urmimala Biswas

The medical device industry is undergoing a profound change in 2025, driven by advancements in generative AI and agentic AI. At the forefront of this revolution are players like NVIDIA ( - Free Report) , whose AI computing platforms are accelerating AI-powered medical applications and capturing investors’ attention. NVIDIA’s Clara platform, powered by generative AI, is enabling real-time medical imaging enhancements and predictive diagnostics.